Terms: = Breast cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
442 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
3. Multifunctional iron-apigenin nanocomplex conducting photothermal therapy and triggering augmented immune response for triple negative breast cancer.
Chen R; Jiang Z; Cheng Y; Ye J; Li S; Xu Y; Ye Z; Shi Y; Ding J; Zhao Y; Zheng H; Wu F; Lin G; Xie C; Yao Q; Kou L
Int J Pharm; 2024 Apr; 655():124016. PubMed ID: 38503397
[TBL] [Abstract] [Full Text] [Related]
4. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract] [Full Text] [Related]
5. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
6. Primary breast rhabdomyosarcoma in a 17-year-old girl.
Singotia L; Haritha VS
J Cancer Res Ther; 2023 Oct; 19(7):2070-2071. PubMed ID: 38376322
[TBL] [Abstract] [Full Text] [Related]
7. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
Sala I; Pagan E; Pala L; Oriecuia C; Musca M; Specchia C; De Pas T; Cortes J; Giaccone G; Postow M; Gelber RD; Bagnardi V; Conforti F
Front Immunol; 2024; 15():1340979. PubMed ID: 38348030
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic implication of novel immune-related signature in breast cancer.
Chen B; Wu H; Fang Y; Huang G; Guo C; Chen C; He L; Chen Z; Hou X; Li C; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37065. PubMed ID: 38335435
[TBL] [Abstract] [Full Text] [Related]
9. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
10. The anti-PD-L1/ctla-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Li Q; Liu J; Zhang Q; Ouyang Q; Zhang Y; Liu Q; Sun T; Ye F; Zhang B; Xia S; Zhang B; Xu B
Nat Commun; 2024 Feb; 15(1):1015. PubMed ID: 38310192
[TBL] [Abstract] [Full Text] [Related]
11. Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer.
Kina Kilicaslan U; Aru B; Aydin Aksu S; Vardar Aker F; Yanikkaya Demirel G; Gurleyik MG
Surg Oncol; 2024 Feb; 52():102037. PubMed ID: 38290327
[TBL] [Abstract] [Full Text] [Related]
12. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
[TBL] [Abstract] [Full Text] [Related]
13. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive breast cancer.
Chi W; Xiu B; Xiong M; Wang X; Li P; Zhang Q; Hou J; Sang Y; Zhou X; Chen M; Zheng S; Zhang L; Xue J; Chi Y; Wu J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203393
[TBL] [Abstract] [Full Text] [Related]
14. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
16. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract] [Full Text] [Related]
17. Dual silencing of tumor-intrinsic VISTA and ctla-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract] [Full Text] [Related]
18. Effects of the CALM intervention on resilience in Chinese patients with early breast cancer: a randomized trial.
Liu S; Huang R; Li A; Yu S; Yao S; Xu J; Tang L; Li W; Gan C; Cheng H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18005-18021. PubMed ID: 37980293
[TBL] [Abstract] [Full Text] [Related]
19. The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer.
Bimonte VM; Catanzaro G; Po A; Trocchianesi S; Besharat ZM; Spinello Z; Curreli M; Fabi A; Bei R; Milella M; Vacca A; Ferretti E; Migliaccio S
Endocrine; 2024 Mar; 83(3):798-809. PubMed ID: 37979099
[TBL] [Abstract] [Full Text] [Related]
20. Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity.
Zhu M; Zhao Q; Zhang W; Xu H; Zhang B; Zhang S; Duan Y; Liao C; Yang X; Chen Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111168. PubMed ID: 37939513
[TBL] [Abstract] [Full Text] [Related]
[Next]